UK Favors Post-Brexit EMA/MHRA ‘Mutual Recognition’ Deal
Jeremy Hunt, the UK Secretary of State for Health, has told a parliamentary committee that the EMA is likely to leave the UK but that his government will be seeking a close relationship with the agency that could involve the mutual recognition by the UK regulator of EU drug approvals.
You may also be interested in...
The UK is on track to start formal EU exit negotiations in March, Denmark has announced its official candidacy to host the European Medicines Agency post-Brexit, and details are emerging on the campaigns that other contenders for the EMA, such as Ireland and Italy, are waging.
The Dutch government says it is well placed to host the European Medicines Agency, citing good travel links, the ability to host international organizations, and the prospect of continuity of the agency’s work. It wants a decision to be taken soon on the EMA’s future location.
The European Medicines Agency is working to ensure it can cope with the many challenges it will face as a result of the UK leaving the EU. Those challenges could include the agency losing 50% of its staff, according to the EMA’s deputy head Noel Wathion.